Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HEXA | P06865 | 1/20 | 0.49 |
| ▸ | HEXB | P07686 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274320 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL19541802 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL30392446 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL30392640 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL5371487 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL23720311 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL3892107 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL30274282 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL230525 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT | |
| SCHEMBL26813895 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDNPSR1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111303006-B | Preparation method of amlodipine key intermediate | 常州大学 | 2021-10-12 | — | — | CN | claimed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025034849-A1 | FUSED PYRIDAZINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4426700-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024144088-A1 | MET PROTEIN DEGRADATION INDUCING COMPOUND | ONCOZEN CO., LTD. (KR) | 2024-07-04 | — | — | WO | disclosed |
| US-5688941-A | Methods of making conjugated 4' desmethyl nucleoside analog compounds | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5608046-A | Conjugated 4'-desmethyl nucleoside analog compounds | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5514654-A | ANTITUMOR AGENTS AND IMMUNOMODULATORS | UNIV LJUBLJANI (SI) | 1996-05-07 | — | — | US | disclosed |
| WO-1996010030-A1 | OLIGOMERS HAVING HETEROATOM-LINKED CONJUGATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| EP-0477912-A2 | Novel N-acyldipeptides, processes for the preparation thereof and pharmaceutical compositions containing the same | UNIVERZA EDVARDA KARDELJA V LJUBLJANI, VDO FAKULTETA ZA NARAVOSLOVJE IN TEHNOLOGIJO, N.SOL.O., LUBLJANA (YU) | 1992-04-01 | — | — | EP | disclosed |
| US-5026863-A | Medicinal products in racemic or enantiomorph form; calcium channel blockers. hypotensive agents, cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1991-06-25 | — | — | US | disclosed |
| EP-0278621-B1 | SUBSTITUTED AMINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4987130-A | ANTIARRHYTHMIA AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4983740-A | Multistep; from 2- 2-/2-chloroethoxy/ethoxy!ethanol and potassium phthalimide | ADIR ET COMPAGNIE (FR) | 1991-01-08 | — | — | US | disclosed |
| US-4870091-A | CALCIUM CHANNEL BLOCKERS | ADIR ET CIE (FR) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | SMN1; SMN2 2413/4885HPGD 3207/4885NPSR1 3590/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | SMN1; SMN2 737/4885HPGD 4011/4885NPSR1 3519/4885 |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | SMN1; SMN2 1873/4885HPGD 854/4885NPSR1 4391/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | SMN1; SMN2 2654/4885HPGD 18/4885NPSR1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.